How did GT Biopharma's expenses impact profits in Q4 2024?

GT Biopharma's expenses had a significant negative impact on profits in Q4 2024. The company's net income was -$3.78 million for the quarter, which can be attributed to the high operating expenses, research and development expenses, and general and administrative expenses. The total expenses for the quarter were not provided, but the fact that the net income was negative indicates that the expenses were greater than the revenue generated during the period. This suggests that GT Biopharma faced considerable challenges in managing its costs and generating sustainable profitability in Q4 2024. |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Operating Expenses|market_code| |---|---|---|---|---|---|---|---| |GTBP|GTBP.O|GT Biopharma|2024 Q1|2314000|777000||186| |GTBP|GTBP.O|GT Biopharma|2024 Q2|2122000|1784000||186| |GTBP|GTBP.O|GT Biopharma|2024 Q3|2297000|1307000||186| |GTBP|GTBP.O|GT Biopharma|2024 Q4|1833000|1930000||186| |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Net Income|market_code| |---|---|---|---|---|---|---|---| |GTBP|GTBP.O|GT Biopharma|2024 Q1|2314000|777000|-2266000|186| |GTBP|GTBP.O|GT Biopharma|2024 Q2|2122000|1784000|-3710000|186| |GTBP|GTBP.O|GT Biopharma|2024 Q3|2297000|1307000|-3411000|186| |GTBP|GTBP.O|GT Biopharma|2024 Q4|1833000|1930000|-3775000|186|